摘要
为探讨基质金属蛋白酶 9(MMP 9)及其抑制剂 (TIMP 1)在单侧肾切除后 ,重复注射阿霉素复制肾小球硬化大鼠肾小管 间质的表达 ,以及厄贝沙坦对其的影响和可能的保护作用机制。将肾小球硬化大鼠分为厄贝沙坦治疗组和对照组 ,设假手术组为正常对照。检测厄贝沙坦治疗 4周后 ,肾功能和组织病理改变 ,并用免疫组化或原位杂交的方法分别检测肾小球和肾小管 间质中MMP 9/TIMP 1、转化生长因子 β1(TGF β1)的表达。结果表明肾小球硬化组肾小管中MMP 9、TIMP 1、TGF β1显著增加。厄贝沙坦组中肾小管中上述指标表达下降。提示厄贝沙坦在延缓肾小球硬化同时 ,在减轻肾小管 间质纤维化方面有一定保护作用。
The present study was designed to assess whether expression of metalloproteinase9 (MMP 9) and its tissue inhibitor of metalloproteinase1 (TIMP 1) induced by transforming growth factorβ1(TGF β1 ) in tubulointerstitial is affected by irbersantan during the early stage of focal glomerular sclerosis (FGS). Rats received twice intravenous injections of adriamycin (ADR) after the right kidney removed. Those rats were randomly assigned to irbesatan treatment group and control group. Treatment group was received 50mg/(kg·d) irbesartan for 4 weeks. Rats with sham operation served as normal control. Proteinurina and serum creatinine were measured after treatment. Renal histopathological changes were evaluated as well. Immunohistochemistry was used to examine the protein expression of TGF β1?MMP 9 and TIMP 1. The mRNA levels of MMP 9 and TIMP 1 were detected by in situ hybridization. The results were graded according to the intensity of staining. Urinary protein in treatment group were significantly lower than that of control group,but serum creatinine didn't show any change; TGF β1?TIMP 1 and MMP 9 were significantly lower than that of control group in tubulointerstitial and consistently associated with tubular degeneration and interstitial fibrosis progressed.MMP 9/TIMP 1 were involced in the progression of this disease,and irbesartan has a renoprotective effect on tubulointerstitial fibrosis in focal glomerular sclerosis rats.
出处
《基础医学与临床》
CSCD
北大核心
2002年第6期554-558,共5页
Basic and Clinical Medicine
